Biomarkers in Patients With Advanced Rhabdomyosarcoma

Status Completed

Clinical Trial Summary

This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be Involved in the paired box (Pax)3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas.

OUTLINE:

Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis. ;

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Adult Rhabdomyosarcoma
Childhood Alveolar Rhabdomyosarcoma
Childhood Embryonal Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Childhood Rhabdomyosarcoma
Rhabdomyosarcoma
Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Clinical Trial Details

NCT number	NCT01668095
Study type	Observational
Source	Children's Oncology Group
Contact
Status	Completed
Phase	N/A
Start date	August 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00245102` - Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	Phase 2
Completed	`NCT01206140` - Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT01222715` - Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma	Phase 2
Completed	`NCT01553539` - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00098579` - Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery	Phase 1
Completed	`NCT00004241` - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Phase 1
Completed	`NCT01462630` - Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma	Phase 2
Completed	`NCT01016015` - Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Phase 2
Terminated	`NCT00087191` - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer	N/A
Completed	`NCT00084630` - Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans	Phase 2
Completed	`NCT01782313` - A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas	Phase 2
Completed	`NCT02357810` - Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas	Phase 2
Terminated	`NCT00233948` - Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Completed	`NCT00919269` - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Completed	`NCT01532687` - Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma	Phase 2
Completed	`NCT01154452` - Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Phase 1/Phase 2
Completed	`NCT00937495` - Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma	Phase 2
Completed	`NCT00720174` - Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma	Phase 1
Completed	`NCT00330421` - Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)	Phase 2